Metrics to compare | WANB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipWANBPeersSector | |
|---|---|---|---|---|
P/E Ratio | 12.3x | 31.2x | −0.3x | |
PEG Ratio | 0.41 | 0.67 | 0.00 | |
Price/Book | 4.8x | 4.1x | 2.6x | |
Price / LTM Sales | 1.1x | 4.1x | 3.0x | |
Upside (Analyst Target) | - | 7.3% | 58.2% | |
Fair Value Upside | Unlock | −4.2% | 7.5% | Unlock |
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. It offers formulations for anti-infectives, pain and analgesics, gastroenterology, rheumatology, respiratory, gynecology, and central nervous system, as well as for vitamins, minerals, and nutrition. The company also provides API products for antidiabetics, antidepressants, anti-histaminic, anaesthetic, anti-inflammatory, anti-coagulant, GERD, and gastric ulcer therapy, as well as antitussives and analgesics. Its API portfolio includes Metformin Hcl, Sertraline Hcl, Tramadol Hcl, Mefenamic Acid , Metformin Hcl DC, Diphenhydramine Citrate, Paroxetine, Diphenhydramine Hcl, and Anaesthetic API. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was founded in 1988 and is headquartered in Navi Mumbai, India.